FindTrial
Sign In

LGX818

DRUG12 trials

Sponsors

Pfizer, Array BioPharma, Memorial Sloan Kettering Cancer Center, Array Biopharma, now a wholly owned subsidiary of Pfizer, Fondazione Melanoma Onlus

Conditions

Colorectal CancerHematologic MalignanciesLocally Advanced Metastatic BRAF Mutant MelanomaMelanomaMelanoma and Metastatic Colorectal CancerMetastatic Colorectal CancerMetastatic MelanomaNon-Small Cell Lung Cancer

Phase 1

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CompletedNCT01436656
PfizerMelanoma and Metastatic Colorectal Cancer
Start: 2011-09-05End: 2022-11-07Updated: 2024-10-28
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
CompletedNCT01543698
PfizerSolid Tumors Harboring a BRAF V600 Mutation
Start: 2012-05-28End: 2023-03-09Updated: 2024-03-13
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
TerminatedNCT01777776
Array BioPharmaLocally Advanced Metastatic BRAF Mutant Melanoma
Start: 2013-07-31End: 2015-04-30Updated: 2016-09-13
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
CompletedNCT02278133
Array BioPharmaMetastatic Colorectal Cancer
Start: 2014-12-31End: 2017-06-23Updated: 2017-10-09

Phase 2

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
CompletedNCT01719380
PfizerColorectal Cancer
Start: 2012-11-23End: 2019-02-12Updated: 2021-06-23
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
TerminatedNCT01820364
Array BioPharmaMelanoma
Start: 2013-11-30End: 2015-03-31Updated: 2017-01-09
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
CompletedNCT01894672
Memorial Sloan Kettering Cancer CenterMelanoma
Start: 2013-07-31End: 2016-03-17Updated: 2024-07-16
LGX818 for Patients With BRAFV600 Mutated Tumors
TerminatedNCT01981187
PfizerHematologic Malignancies, Solid Tumor
Start: 2014-01-14End: 2015-10-13Updated: 2021-03-26
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
WithdrawnNCT02109653
Array Biopharma, now a wholly owned subsidiary of PfizerNon-Small Cell Lung Cancer
Start: 2015-06-30End: 2017-11-30Updated: 2020-11-13
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
CompletedNCT02159066
PfizerMelanoma
Start: 2014-07-23End: 2023-01-10Updated: 2024-03-05
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
CompletedNCT02631447
Fondazione Melanoma OnlusMetastatic Melanoma
Start: 2016-11-14End: 2024-05-31Updated: 2024-06-07

Phase 3

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
CompletedNCT01909453
PfizerMelanoma
Start: 2013-09-12End: 2024-09-03Updated: 2026-02-27

Related Papers

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.
2026-08-04
Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial.
2025-07-01
Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.
Journal of Clinical Oncology2025-05-281 citations
Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for predictive spatial biomarker identification on immunotherapy-treated melanoma patients.
Journal of Clinical Oncology2025-05-28
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i> V600-Mutant Metastatic Melanoma
Clinical Cancer Research2025-03-192 citations
A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.
2024-11-014 citations
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
NEJM Evidence2024-09-247 citations
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
2024-04-2436 citations
Abstract 5168: Analysis of biomarker and outcomes data: 7-year update from COLUMBUS
Cancer Research2024-03-22
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
2024-01-0252 citations
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasis
Neuro-Oncology Advances2024-01-015 citations
A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [<scp><sup>14</sup>C</scp>] encorafenib in healthy male subjects
Pharmacology Research & Perspectives2023-09-298 citations
Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
Melanoma Research2023-08-036 citations
A plain language summary of the 5-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Future Oncology2023-05-0111 citations
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer
The Oncologist2023-02-2246 citations
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
BMC Health Services Research2023-01-186 citations
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology2022-09-01204 citations
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma
Journal of Clinical Oncology2022-07-21173 citations
Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study
Cancer Research2022-06-15
Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.
Journal of Clinical Oncology2022-06-0115 citations

23 more papers not shown